References
- 1. Kommaraju K, Latifi M. Outpatient management of asthma in adults: A snapshot of the 2020 GINA report. Cleve Clin J Med. 2021;88:377-380.10.3949/ccjm.88a.20167
- 2. Wang E, Wechsler ME, Tran TN, et al. Characterization of Severe Asthma Worldwide: Data From the International Severe Asthma Registry. Chest. 2020;157:790-804.10.1016/j.chest.2019.10.053
- 3. Burney P, Jarvis D, Perez-Padilla R. The global burden of chronic respiratory disease in adults. Int J Tuberc Lung Dis. 2015;19:10-20.10.5588/ijtld.14.0446
- 4. Menzies-Gow A, Corren J, Bel EH, et al. Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial. ERJ Open Res. 2019;5:00009-2019.10.1183/23120541.00009-2019
- 5. Park HS, Kim MK, Imai N, et al. Asian Benralizumab Study Group. A Phase 2a Study of Benralizumab for Patients with Eosinophilic Asthma in South Korea and Japan. Int Arch Allergy Immunol. 2016;169:135-145.10.1159/000444799
- 6. Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013;132:1086-1096.10.1016/j.jaci.2013.05.020
- 7. Bagnasco D, Heffler E, Testino E, Passalacqua G, Canonica GW. Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment. Expert Opin Drug Metab Toxicol. 2019;15:113-120.10.1080/17425255.2019.1568409
- 8. Goldman M, Hirsch I, Zangrilli JG, Newbold P, Xu X. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies. Curr Med Res Opin. 2017;33:1605-1613.10.1080/03007995.2017.1347091
- 9. O’Quinn S, Xu X, Hirsch I. Daily patient-reported health status assessment improvements with benralizumab for patients with severe, uncontrolled eosinophilic asthma. J Asthma Allergy. 2019;12:21-33.10.2147/JAA.S190221
- 10. Dunican EM, Fahy JV. Asthma and corticosteroids: time for a more precise approach to treatment. Eur Respir J. 2017;49:1701167.10.1183/13993003.01167-2017
- 11. Pazdrak K, Moon Y, Straub C, Stafford S, Kurosky A. Eosinophil resistance to glucocorticoid-induced apoptosis is mediated by the transcription factor NFIL3. Apoptosis. 2016;21:421-431.10.1007/s10495-016-1226-5
- 12. Molfino NA, Gossage D, Kolbeck R, Parker JM, Geba GP. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clin Exp Allergy. 2012;42:712-737.10.1111/j.1365-2222.2011.03854.x
- 13. Varricchi G, Bagnasco D, Borriello F, Heffler E, Canonica GW. Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: Evidence and unmet needs. Curr Opin Allergy Clin Immunol. 2016;16:186-200.10.1097/ACI.0000000000000251
- 14. Pham TH, Damera G, Newbold P, Ranade K. Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respir Med. 2016;111:21-29.10.1016/j.rmed.2016.01.003
- 15. O’Quinn S, Xu X, Hirsch I. Daily patient-reported health status assessment improvements with benralizumab for patients with severe, uncontrolled eosinophilic asthma. J Asthma Allergy. 2019;12:21-33.10.2147/JAA.S190221
- 16. van Dijk BCP, Svedsater H, Heddini A, Nelsen L, Balradj JS, Alleman C. Relationship between the Asthma Control Test (ACT) and other outcomes: a targeted literature review. BMC Pulm Med. 2020;20:79.10.1186/s12890-020-1090-5